COMPASS Pathways: COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II

Related Keywords

London ,City Of ,United Kingdom ,United States ,Phoenix ,Arizona ,California ,La Jolla ,Friston ,East Sussex ,America ,David Feifel ,Sheppard Pratt Baltimore ,Stephen Schultz ,Amy Lawrence ,Sheppard Pratt ,Scott Aaronson ,Institute For Advanced Diagnostics ,Linkedin ,Young ,Kadima Neuropsychiatry Institute ,Nasdaq ,Exchange Commission ,National Institute Of Mental Health ,Meeting Of The American College Neuropsychopharmacology ,Annual Meeting ,American College ,Depression Rating Scale ,Chief Science Officer ,Advanced Diagnostics ,Principal Investigator ,New England Journal ,Guy Goodwin ,Chief Medical Officer ,Emotional Breakthrough Inventory ,Five Dimensional Altered States ,North America ,Securities Act ,Private Securities Litigation Reform Act ,Open Label Study ,Compass ,Pathways ,Omp360 ,Silocybin ,Therapy ,Shows ,Potential ,Pen ,Label ,Study ,Type ,Bipolar ,Disorder ,Resented ,Cnp ,